Treatment of progressive multiple sclerosis: what works, what does not, and what is needed

A Feinstein, J Freeman, AC Lo - The Lancet Neurology, 2015 - thelancet.com
Disease-modifying drugs have mostly failed as treatments for progressive multiple sclerosis.
Management of the disease therefore solely aims to minimise symptoms and, if possible …

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

D Ontaneda, RJ Fox, J Chataway - The Lancet Neurology, 2015 - thelancet.com
Progressive multiple sclerosis is characterised clinically by the gradual accrual of disability
independent of relapses and can occur with disease onset (primary progressive) or can be …

Symptomatic therapy and neurorehabilitation in multiple sclerosis

J Kesselring, S Beer - The Lancet Neurology, 2005 - thelancet.com
Multiple sclerosis (MS) is associated with a variety of symptoms and functional deficits that
result in a range of progressive impairments and handicap. Symptoms that contribute to loss …

Secondary progressive multiple sclerosis: current knowledge and future challenges

M Rovaris, C Confavreux, R Furlan, L Kappos… - The Lancet …, 2006 - thelancet.com
The secondary progressive phase of multiple sclerosis (MS), which is characterised by a
steady accrual of fixed disability after an initial relapsing remitting course, is not clearly …

Evolving concepts in the treatment of relapsing multiple sclerosis

G Comi, M Radaelli, PS Sørensen - The Lancet, 2017 - thelancet.com
In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The
increasing availability of effective disease-modifying therapies has shifted the aim of …

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

D Ontaneda, E Tallantyre, T Kalincik… - The Lancet …, 2019 - thelancet.com
Treatment decisions in multiple sclerosis are complex given the large number of disease-
modifying therapies with diverse safety and efficacy profiles. The importance of early …

Primary-progressive multiple sclerosis

DH Miller, SM Leary - The Lancet Neurology, 2007 - thelancet.com
Summary About 10–15% of patients with multiple sclerosis (MS) present with gradually
increasing neurological disability, a disorder known as primary-progressive multiple …

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function

D Ontaneda, AJ Thompson, RJ Fox, JA Cohen - The Lancet, 2017 - thelancet.com
Multiple sclerosis is a major cause of neurological disability, which accrues predominantly
during progressive forms of the disease. Although development of multifocal inflammatory …

Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions

AJ Thompson, AT Toosy, O Ciccarelli - The Lancet Neurology, 2010 - thelancet.com
Management of symptoms in multiple sclerosis (MS) has received little attention compared
with disease-modifying treatments. However, the effect of these symptoms on quality of life …

Progressive multiple sclerosis

D Ontaneda, RJ Fox - Current opinion in neurology, 2015 - journals.lww.com
PMS represents a significant challenge, as the pathogenesis of the disease is not well
understood, no validated outcome metrics have been established and clinical trial …